Atara Biotherapeutics
ATRA
116 hedge funds and large institutions have $1.01B invested in Atara Biotherapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 24 reducing their positions, and 25 closing their positions.
169% more call options, than puts
Call options by funds: $4.18M | Put options by funds: $1.56M
117% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 24
0.11% more ownership
Funds ownership: 4.23% → 4.34% (+0.11%)
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
3% less funds holding
Funds holding: 120 → 116 (-4)
48% less capital invested
Capital invested by funds: $1.94B → $1.01B (-$930M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$38.4M |
| 2 |
Morgan Stanley
New York
|
+$20.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.6M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
+$17.5M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$42M |
| 3 |
HCM
Highline Capital Management
New York
|
-$11M |
| 4 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$10.9M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$7.69M |
ATRA Hedge Fund Activity: Q2 2019 in Review
116 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2019, worth a combined $1.01B — down 48% from $1.94B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ATRA and 23 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 52 added.
The largest buyer was Maverick Capital, adding an estimated $38.4M. The largest seller was Fidelity Investments, cutting an estimated $53.7M.
- 116 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2019, down from 120 in Q1 2019.
- Funds reported $1.01B of Atara Biotherapeutics stock for Q2 2019, down 48% quarter-over-quarter.
- 23 funds opened new Atara Biotherapeutics positions in Q2 2019 and 25 closed out, a net change of -2 holders.
- The largest Atara Biotherapeutics buyer in Q2 2019 was Maverick Capital, an estimated $38.4M added.
- The largest Atara Biotherapeutics seller in Q2 2019 was Fidelity Investments, an estimated $53.7M sold.
Based on aggregated 13F filings for Q2 2019.